LXP vs MPT
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LXP exhibits a severe divergence between its current market price ($50.16) and its deterministic value markers, with a Piotroski F-Score of 4/9 indicating only marginal stability. The stock trades at a significant premium to both its Graham Number ($33.20) and its growth-based intrinsic value ($10.43). Fundamental deterioration is evident through negative YoY revenue and earnings growth, coupled with an unsustainable dividend payout ratio of 149.73%. Despite recent price appreciation, the technical trend is heavily bearish (10/100), suggesting a potential correction to align with poor underlying fundamentals.
MPT exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 2/9, indicating weak fundamental health. While the stock trades at a discount to book value (P/B 0.66), this is offset by a catastrophic dividend payout ratio of 1054.55%, which is fundamentally unsustainable. Despite strong top-line revenue growth of 25.4%, the company suffers from negative profit margins and a consistent track record of massive earnings misses. The combination of high debt/equity (2.12) and bearish insider sentiment suggests a high risk of dividend cuts or further capital erosion.
Compare Another Pair
Related Comparisons
LXP vs MPT: Head-to-Head Comparison
This page compares LXP Industrial Trust (LXP) and Medical Properties Trust, Inc. (MPT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.